Neoplasms, Plasma Cell: all 2,313 studies

Page 11 of 24. Open to participants first (248), then studies with results posted, then the rest; newest registration first within each.

• Biology and Genetics of Smouldering MyelomaStatus unknownNCT05047107
• Feasibility Study of an ePRO Monitoring for Patients With Multiple Myeloma and Development of Item ListsCompletedNCT05036863
• Ph I Study in Adult Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT05027594Phase 1
• A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple MyelomaActive, not recruitingNCT05016778Early Phase 1
• Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple MyelomaWithdrawnNCT05013437Early Phase 1
• Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple MyelomaStatus unknownNCT05008536Early Phase 1
• A Study of KRN125 in Patients With Multiple Myeloma and Malignant LymphomaCompletedNCT05007652Phase 2
• Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple MyelomaStatus unknownNCT05006469Phase 3
• Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple MyelomaTerminatedNCT05000450Phase 1/2
• A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)WithdrawnNCT04998747Phase 1
• Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received LenalidomideStatus unknownNCT04989140Phase 4
• Phase 1 Study of F182112 in Patients With Relapsed or Refractory Multiple MyelomaStatus unknownNCT04984434Phase 1
• Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple MyelomaTerminatedNCT04975399Phase 1
• Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple MyelomaTerminatedNCT04956302Phase 1
• Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy AdultsCompletedNCT04952766Phase 4
• REST - Replacing Steroids in the Transplant IneligbleCompletedNCT04939844Phase 2
• Study of FasT CAR-T GC012F Injection in High Risk TE NDMM PatientsStatus unknownNCT04935580Phase 1/2
• A Study of OPD5 Followed by Autologous Stem Cell Transplant for Patients With Relapsed Refractory Multiple MyelomaWithdrawnNCT04918511Phase 1
• Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY DiseaseTerminatedNCT04912427Phase 1
• Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple MyelomaTerminatedNCT04895410Phase 1
• Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple MyelomaTerminatedNCT04892264Phase 1
• Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMMActive, not recruitingNCT04891809Phase 2
• Selinexor in Combination With Thalidomide and Dexamethasone in RRMMStatus unknownNCT04891744Phase 1/2
• Immunomonitoring and Multiple Myeloma: Impact of Lenalidomide on Immune Checkpoint ExpressionCompletedNCT04872023Not applicable
• Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple MyelomaWithdrawnNCT04864522Phase 1/2
• Repeated HBO Therapy in Myeloma Patients Undergoing High-Dose Therapy and Auto-HCTCompletedNCT04862676Early Phase 1
• Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple MyelomaStatus unknownNCT04861480Phase 1
• A Study of Real-World Use of Ixazomib Citrate in People With Multiple Myeloma (MM)CompletedNCT04840680
• Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and LymphomaStatus unknownNCT04818372Phase 1
• A Dose Escalation Study of LNA-i-Mir-221 for Cancer TreatmentCompletedNCT04811898Phase 1
• Retrospective Study to Describe Carfilzomib Use on Patients With Relapsed Multiple Myeloma in France in the Context of Carfilzomib Nominative Expanded Access and Compassionate UseCompletedNCT04811508
• Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT04808037Phase 1/2
• Analysis of the Immune Parameters of COVID-19 Infection in Patients With Multiple MyelomaTerminatedNCT04805203Not applicable
• Rapid-infusion Isatuximab in Relapsed/Refractory Multiple MyelomaWithdrawnNCT04802031Phase 2
• Study of Selinexor Plus DRd for Newly Diagnosed Multiple MyelomaActive, not recruitingNCT04782687Phase 2
• The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple MyelomaStatus unknownNCT04762745Phase 1/2
• The TOTOM Trial: Tai Chi to Optimize Transplant Outcomes for Multiple MyelomaCompletedNCT04760405Not applicable
• Impact of COVID-19 After Autologous Hematopoietic Stem Cell Transplantation in SwedenCompletedNCT04760184
• CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple MyelomaCompletedNCT04758767Phase 1
• agenT-797 in Participants With Relapsed/Refractory Multiple MyelomaCompletedNCT04754100Phase 1
• Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).Active, not recruitingNCT04751877Phase 3
• A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory MyelomaTerminatedNCT04735575Phase 1/2
• A Study to Evaluate the My Hematology Oncology Patient Experience (MyHOPE™) For Multiple Myeloma (MM) Digital Care Network in Patients With MMTerminatedNCT04730505Phase 1
• MGUS, SMM, and MM Patient Experience With Coronavirus 19 (COVID-19) SurveyStatus unknownNCT04727294
• Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM)CompletedNCT04721002
• Novel BCMA-targeted CAR-T Cell Therapy for Multiple MyelomaStatus unknownNCT04706936Phase 1
• A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma PatientsStatus unknownNCT04688853Phase 1
• Mycobiome Supporting Diet to Reduce GI Toxicity Associated With ASCTWithdrawnNCT04685525Not applicable
• A Single-centre Prospective Study to Explore the Role of Frailty in Patients With Multiple Myeloma.CompletedNCT04683393
• Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple MyelomaActive, not recruitingNCT04680468Phase 2
• Evaluation of Clinical Treatment of Multiple Myeloma Based on Multi-omicsStatus unknownNCT04678089
• APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple MyelomaStatus unknownNCT04674514Phase 1/2
• Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT04671251Phase 1
• A Study to Investigate the Relationship Between Duration of Treatment and Response in Patients With Multiple Myeloma (MM) or Systemic AL Amyloidosis Treated in Real-life PracticeCompletedNCT04659798
• CORONADO (Circulating tumOur pROtein quaNtification cApillary blooD cOvid-19)Status unknownNCT04659252
• Clinical Study of T Cell Infusion Targeting BCMA Chimeric Antigen ReceptorCompletedNCT04650724Early Phase 1
• Anti-BCMA CAR-T Cell Therapy for the R/R Multiple MyelomaStatus unknownNCT04637269Early Phase 1
• Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma PatientsCompletedNCT04634435Phase 1
• CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple MyelomaStatus unknownNCT04626752Early Phase 1
• BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple MyelomaStatus unknownNCT04617704Early Phase 1
• FT538 in Subjects With Advanced Hematologic MalignanciesTerminatedNCT04614636Phase 1
• Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT04613557Phase 1
• Vertebral Fat Quantitative MRI as a Marker of Bone Fragility in Multiple Myeloma (MYELOMEFRAGIQUANTI)Status unknownNCT04609150
• A Single-center Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of a BCMA-targeted Universal LCAR-BCX Cells in Patients With Relapsed/Refractory Multiple MyelomaStatus unknownNCT04601935Phase 1
• Randomized Study of Digital Life Coaching in Myeloma Patients Undergoing TransplantationCompletedNCT04589286Not applicable
• Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple MyelomaTerminatedNCT04570631Phase 1
• Clinical Study of Autologous Natural Killer Cells in Multiple MyelomaStatus unknownNCT04558853Phase 1
• Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple MyelomaStatus unknownNCT04537442Phase 1
• Expanded Access Program for Melphalan Flufenamide (Melflufen) in Triple Class Refractory Multiple MyelomaApproved for marketingNCT04534322
• Fermented Milk Supplementation on Symptoms of Disease and Treatment in Patients With Multiple MyelomaCompletedNCT04530812Not applicable
• Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple MyelomaTerminatedNCT04521335Phase 1
• Novel Drugs After Allo-HSCT in Patients With Multiple MyelomaCompletedNCT04506320
• Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple MyelomaSuspendedNCT04505813Phase 1/2
• Clinical Study to Evaluate the Safety and Feasibility of spCART-269 Injection in the Treatment of MMStatus unknownNCT04500431Phase 1
• A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple MyelomaActive, not recruitingNCT04499339Phase 1/2
• COVID-19 Infection and Multiple MyelomaCompletedNCT04492371
• Virtual Exercise for Multiple MyelomaCompletedNCT04484714Not applicable
• A Study of PET/CT Scans With the Radioactive Tracer 89Zr-DFO-Daratumumab in People With MyelomaWithdrawnNCT04467281Phase 2
• Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple MyelomaWithdrawnNCT04466475Phase 1
• Expanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple MyelomaNo longer availableNCT04453397
• Individual Patient Investigational New Drug (IND) Expanded Access Program of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Participant With Multiple MyelomaNo longer availableNCT04452994
• Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple MyelomaStatus unknownNCT04447573Not applicable
• Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple MyelomaCompletedNCT04445701Phase 1/2
• Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)WithdrawnNCT04439305Phase 2
• Digital Life Coaching for Myeloma Patients Undergoing TransplantationCompletedNCT04432818Not applicable
• A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MMStatus unknownNCT04412889Early Phase 1
• Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell TherapyCompletedNCT04409314
• A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT04398485Phase 1
• A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple MyelomaCompletedNCT04394650Phase 1
• eHealth for the ElderlyCompletedNCT04393090
• Iberdomide Combined With Low-dose Cyclophosphamide and DexamethasoneActive, not recruitingNCT04392037Phase 2
• Multiple Myeloma (MM) Quality of Life (QOL) StudyStatus unknownNCT04388735
• Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma PatientsCompletedNCT04379817Phase 2
• Pilot Study of an Oral Chemotherapy Teaching Tool to Improve Adherence in Patients With Multiple MyelomaStatus unknownNCT04376957Not applicable
• CTFEA Myeloma StudyStatus unknownNCT04364724
• INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple MyelomaWithdrawnNCT04355039Phase 1
• COM902 (A TIGIT Inhibitor) in Subjects With Advanced MalignanciesCompletedNCT04354246Phase 1
• Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma PatientsWithdrawnNCT04348006Phase 4
• A Study of Ninlaro in Real World Clinical Practice in ChinaCompletedNCT04328662
• Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody.Active, not recruitingNCT04309981Phase 1/2

← Neoplasms, Plasma Cell overview